|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We suggest that SET/TAF-Iα might be a tumor suppressing factor regulated by miR-21-5p in lung adenocarcinoma.
|
31176779 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor binding protein 7 (IGFBP7) has recently been recognized as a tumor suppressor in many cancer types.
|
31183073 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Univariate and multivariate analysis showed that IGFBP7 expression and tumor stage were independent
|
29580038 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The OS and PSF were significantly enhanced in patients with lower expression of CD105 in both tumor tissue and PB compared to those with higher expression of CD105 in both tumor tissue and PB (12.4 vs 8.5, P < 0.001, 8.5 vs 6.5, P < 0.001).
|
29799303 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
When the molecular profiles of the cells were compared based on the drug sensitivities, we found that cancer cells with lower mRNA expression levels of IGFBP7, a tumor suppressor gene that inhibits the activation of insulin-like growth factor-1 receptor (IGF-1R), were less sensitive to pan-HER inhibitors.
|
29465762 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We next investigated the potential mechanism involving in IGFBP7-induced tumour suppression and found that increased expression of IGFBP7 resulted in decrease of IGF-IR, IRS-1 and phosphor-AKT protein levels, accompanied with elevation of phorsphor-p38MAPK.
|
29991293 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
IGFBP7 methylation was observed in 90% of tumor tissues and 59% of controls (P=.0002).
|
27775181 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGFBP7 abrogates tumors by inhibiting angiogenesis and inducing cancer-specific senescence and apoptosis.
|
28619711 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGFBP-rP1 acts as a potential tumor suppressor via the suppression of ERK signaling pathway in endometrial cancer cells.
|
29067463 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The markers significantly overexpressed already in earlier tumor stages (pT1-2) of both histological subtypes (n = 19) have been clustered in a "diagnostic signature": PLA2G7, PRAME, MMP1, MMP3, MMP12, LIlRB2, TREM2, CHST2, IGFBP2, IGFBP7, KCNJ8, EMILIN2, CTHRC1, EMR2, WDR72, LPCAT1, COL4A2, CCL4, and SNX10.
|
26631031 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We show here that in contrast to its tumor-suppressor function in epithelial cells, IGFPB7 can promote anchorage-independent growth in malignant mesenchymal cells and in epithelial cells with an EMT phenotype when IGFBP7 is expressed by the tumor cells themselves and can induce colony formation in colon cancer cells co-cultured with IGFBP7-expressing CAFs by a paracrine tumor-stroma interaction.
|
24632618 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor binding protein 7 (IGFBP7) is reported to have tumour suppressor function through an IGF-dependent pathway in various malignant tumours.
|
26043748 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGFBP-7 induced the apoptosis of tumor and potentially predicted the clinical outcome in some cancers is further demonstrated.
|
25880247 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we reported that insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1), a potential tumor suppressor, controls EMT in colorectal cancer progression.
|
25789970 |
2015 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Since aberrant IGFBP7 expression was observed in a variety of neoplasia and was relevant for prognosis in T-ALL, we investigated the functional role of IGFBP7 in Jurkat and Molt-4 cells as in vitro models for T-ALL.
|
26450156 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein expression analysis of HGSC samples revealed that the large majority of tumour cores (72.6%) showed low or absence of IGFBP7 staining and revealed a significant correlation between IGFBP7 protein expression and a prolonged overall survival (p = 0.044).
|
25886299 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor binding protein 7 (IGFBP7) is known as a tumor suppressor in colorectal cancer (CRC).
|
24427302 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor tissues (73.9 %) had concurrent methylation of two or more genes, with the most frequent combination as KLOTHO and IGFBP7 (53.8 %).
|
24852431 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Increasing evidence suggests that IGFBP-rP1 acts as a tumor suppressor.
|
24513543 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Univariate analysis showed that low expression of IGFBP7 was associated with poor prognosis (P < 0.001), and multivariate analysis showed that IGFBP7 (HR = 1.87; 95 % CI 1.65-2.17), distant metastasis (HR = 2.68; 95 % CI 1.58-4.56), and tumor size (HR = 1.45; 95 % CI 0.90-2.32) were independent prognostic factors for gastric cancer patients.
|
24894674 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IGFBP7 mRNA levels were significantly lower in glioma tissue (n = 120) than in normal brain tissue (n = 20).Low (i.e. below the median, 5.9) IGFBP7 mRNA levels were significantly associated with larger tumour size (≥ 5 cm, compared with <5 cm, diameter).
|
24743871 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a nude mice subcutaneous model, xenografts from human HCC cells were established in both flanks and only left-sided tumors received intratumoral injection of Ad.IGFBP7.
|
23319057 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor-binding protein-7 (IGFBP7) was suggested to function as a tumor suppressor gene in several cancers, and to play a role in the proliferation of keratinocytes.
|
23543219 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CTBP1-AS also exhibits global androgen-dependent functions by inhibiting tumour-suppressor genes via the PSF-dependent mechanism thus promoting cell cycle progression.
|
23644382 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGFBP-rP1 was down-regulated in primary breast cancer tissues and several breast cancer cell lines but overexpressed in senescent human mammary epithelial cells (HMECs), suggesting that IGFBP-rP1 might be a tumor suppressor in breast cancer and the tumor suppressor role of IGFBP-rP1 might be associated with cellular senescence.
|
22392074 |
2012 |